Press releaseBusiness Wire
Charles River Laboratories International
CRL · NYSE
$315.45+$15.43 (+5.14%)TodayMarket closed ·
Prev close $300.02
Latest news
- Press releaseBusiness Wire
Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call
- Press releaseBusiness Wire
Charles River and Autolomous Partner to Transform Laboratory Execution Systems
- NewsPiero Cingari
S&P 500 Erases Losses as US, Iran Reportedly Discuss Hormuz Deal: Stock Market Today
- NewsAvi Kapoor
Everpure, Fervo Energy, Charles River Laboratories And Other Big Stocks Moving Higher On Thursday
- News
Charles River Laboratories International Reiterates FY26 Revenue, Non-GAAP Earnings Outlook, Expects FY30 Organic Revenue Growth In Range Of 5% To 7%
- Press releaseBusiness Wire
Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day
- Press releaseBusiness Wire
Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines
- Press releaseBusiness Wire
Charles River Laboratories to Present at Morgan Stanley and Baird Conferences
- Press releaseBusiness Wire
Charles River Modernizes Endosafe® Endotoxin Testing Cartridge Manufacturing with Fully Automated Production Suite
- News
Charles River Laboratories And Medigen Vaccine Biologics Collaborate On Characterization And Validation Of Virus Seed Bank For MVC's Next-Gen Multivalent Enterovirus Vaccine
- Press releaseBusiness Wire
Charles River Laboratories and Medigen Vaccine Biologics Corp Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing
- NewsPiero Cingari
Gold Jumps 4%, Dow Jones Smashes Record Highs: Stock Market Today
- NewsVandana Singh
Charles River Says Biotech Demand Is Back — Bookings Hit Four-Year High
- NewsAvi Kapoor
Wynn Resorts Posts Upbeat Q2 Earnings, Joins Bloomin' Brands, Shopify, Owens Corning And Other Big Stocks Moving Higher On Wednesday
- News
Charles River Q2 Adj. EPS $3.02 Beats $2.74 Estimate, Sales $1.004B Beat $975.687M Estimate
- Press releaseBusiness Wire
Charles River Laboratories Announces Second-Quarter 2026 Results
- Press releaseBusiness Wire
Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call
- Press releaseBusiness Wire
Charles River Provides NGS Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches
- Press releasePRNewswire
Did Charles River Laboratories International, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
- Press releaseBusiness Wire
Charles River Joins Lilly TuneLab to Optimize AI/ML Platform through Nonclinical Testing Expertise
- Press releaseBusiness Wire
Charles River Laboratories to Present at William Blair and Jefferies Conferences
- Press releaseBusiness Wire
Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions
- Press releaseBusiness Wire
Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow
- Press releaseBusiness Wire
Charles River Laboratories Announces First-Quarter 2026 Results
- Press releaseBusiness Wire
Charles River Launches Rat In Vitro Fertility Services Demonstrating Embryology Capabilities
- Press releaseBusiness Wire
Charles River Highlights Effectiveness of VCGs in Toxicology
- Press releaseBusiness Wire
Charles River Laboratories Schedules First-Quarter 2026 Earnings Release and Conference Call
- Press releaseBusiness Wire
Charles River Advances Cardiovascular Health Awareness Through Support of the American Heart Association
- Press releasePRNewswire
NYSE Content Update: Join Us and 6,500+ Attendees at Marquee AI Event HumanX
- Press releaseBusiness Wire
Charles River Laboratories to Present at TD Cowen and Barclays Conferences
- Press releaseBusiness Wire
Charles River Laboratories Provides Update on Planned Divestitures
- Press releaseBusiness Wire
Charles River Laboratories Announces Executive Appointments
- Press releaseBusiness Wire
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance
- Press releaseBusiness Wire
Charles River Laboratories Provides Business Updates
- NewsVandana Singh
Charles River Beat Expectations But Why Is The Stock Falling?
- Press releaseBusiness Wire
Charles River Laboratories Announces Third-Quarter 2025 Results
- NewsPiero Cingari
Trump-Pfizer Deal Pushes Health Care Stocks To Best Rally In 5 Years
- NewsAniket Verma
Mr Wonderful Kevin O'Leary Says Bitcoin, Ethereum Enough To 'Capture The Promise' Of Crypto, Advises Against 'Irrelevant' Tokens
- Press releaseBusiness Wire
Charles River Laboratories Announces Chief Financial Officer Transition
- Press releaseBusiness Wire
Charles River Laboratories Announces Second-Quarter 2025 Results
- Press releaseBusiness Wire
Charles River Laboratories Announces First-Quarter 2025 Results
- Press releaseBusiness Wire
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024 Results and Provides 2025 Guidance
- Press releaseBusiness Wire
Charles River Laboratories Announces Third-Quarter 2024 Results
- Press releaseBusiness Wire
Charles River Laboratories Announces Second-Quarter 2024 Results
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.